Ten years of onchocerciasis elimination in Nigeria, 2015– 2025: a national programme case study
This case study evaluates Nigeria's 2015–2025 national onchocerciasis elimination program, highlighting how coordinated surveillance, laboratory capacity, and evidence-based interventions have successfully eliminated or interrupted transmission in multiple states while identifying ongoing challenges such as insecurity and the need for sustained post-treatment monitoring.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
River blindness is a parasitic disease that has long plagued communities in Africa, causing severe skin conditions and leading to blindness. It is spread by tiny black flies that breed in fast-flowing rivers. When these flies bite a person, they pass on microscopic worms that grow into adults living under the skin. These adults release even smaller larvae that travel through the skin, waiting to be picked up by another fly, continuing the cycle. For decades, the primary way to stop this cycle was to give millions of people a single pill, ivermectin, once a year. This medicine kills the larvae, stopping the flies from picking up the infection. However, giving the pill forever is not the goal. The ultimate aim is to reach a point where the disease is gone completely, so the medicine is no longer needed. This requires proving that the flies are no longer carrying the parasite and that no new infections are happening in the community.
In 2015, Nigeria launched a major national effort to move from simply controlling this disease to eliminating it entirely. A new committee was formed to guide this transition, bringing together health officials, scientists, and international partners. Their task was to map out exactly where the disease was still active and where it had already stopped. At the start of this decade-long journey, the situation was unclear in many places. Some states had no recent data, others were known to have active transmission, and a few were suspected of having already stopped the spread, but no state had officially declared victory. The committee treated each state as a distinct zone to monitor, creating a detailed plan to check the health of the population and the insects that carry the disease.
Over the next ten years, the programme relied on careful observation and testing rather than guesswork. Researchers collected thousands of blood samples from children, looking for specific antibodies that would indicate a recent infection. They also caught thousands of black flies and examined their heads under microscopes to see if they carried the parasite's genetic material. This rigorous surveillance allowed the team to make evidence-based decisions. If the tests showed the disease was gone, they could stop giving the medicine in that area. If the disease was still present, they continued the treatment. This approach also helped them navigate a specific safety concern. In some parts of Africa, the same medicine can cause severe reactions in people who also carry a different parasite called Loa loa. To address this, the team used a special handheld device to check for this co-infection in Nigeria's rainforest regions. They found that the levels of the second parasite were low enough that the medicine remained safe to use, allowing them to proceed without fear of causing harm.
By May 2025, the results of this decade of work were clear and significant. The disease had been officially eliminated in two states, meaning transmission had stopped and the medicine was no longer needed there. In nine other states, the spread of the disease had been interrupted, a major step forward that also allowed them to stop the mass treatment. In total, ivermectin distribution was halted in 140 local government areas, freeing approximately 30.59 million people from the need for annual treatment. While the progress was substantial, the work was not finished. Nineteen other zones were still being evaluated to confirm if the transmission had stopped, and three states remained difficult to access due to security issues, leaving their status uncertain. The programme also identified that three zones were on track to stop transmission by 2030, while one city had been confirmed as free of the disease for a long time.
The success of this national effort offers a clear lesson for large-scale health campaigns. It showed that a coordinated national committee, supported by strong laboratory testing and international partnerships, can effectively guide a country from treating a disease to eradicating it. The ability to stop giving medicine to millions of people without the disease returning is a testament to the power of sustained surveillance and data-driven decisions. However, the authors note that maintaining these gains will require continued vigilance. They emphasize the need to keep monitoring the insect populations even after treatment stops, to find ways to reach areas currently blocked by insecurity, and to secure long-term funding to ensure the disease does not return. The journey from 2015 to 2025 demonstrates that with the right strategy, even a widespread and stubborn disease can be brought under control and eventually removed from the map.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.